EUS-RFA safely treats aldosterone-producing adenomas, offering a less invasive alternative to adrenalectomy with promising outcomes.

Dental caries as a cause of primary hypertension among children and adolescents suggests a new study published in the ...

The following is a summary of “Differences between private and public primary health care centers and differences between men and women in antihypertensive care and cardiovascular prevention in all ...

The following is a summary of "Blood Pressure in Pregnancy and Hypertension 10–14 Years After Delivery," published in the ...

QLS‑111 is a novel topical formulation using Qlaris Bio’s ATP-sensitive potassium channel modulator platform. QLS-111 lowers ...

Introduction Primary hypertension (PH) affects over one billion individuals globally, yet less than 30% achieve controlled blood pressure (BP) with medication. Many patients require a combination of ...

An oft-repeated message is that primary aldosteronism is not rare; it is quite common. An equally urgent message is that ...

A groundbreaking new treatment is offering fresh hope to individuals suffering from primary aldosteronism, a commonly ...

Adequate Sleep Significantly Reduces the Risk of Hypertension in Adolescents Nov. 11, 2024 — Adolescents who meet the recommended guidelines of nine to 11 hours of sleep per day were shown to ...

Introduction Non-communicable diseases cause 74% of global deaths, with cardiovascular diseases as the major contributor. Hypertension, a primary risk factor for cardiovascular disease, is highly ...

Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced positive topline results from two U.S. Phase II clinical trials ...

Postpartum patients with hypertension who were prescribed nifedipine at discharge had an 88% lower readmission rate than ...